A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures.

Trial Profile

A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Zonisamide (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Acronyms CATZ
  • Sponsors Eisai Inc
  • Most Recent Events

    • 03 Oct 2013 Based on data from this trial, Eisai received EC approval extending use of adjunctive Zonegran in the treatment of partial seizures (with or without secondary generalization) to include paediatric patients ≥6 years, according to a media release.
    • 29 Jul 2013 The CHMP of the EMA has issued a positive opinion on on the license extension application for the use of zonisamide in paediatric patients, supported by data from this trial, according to an Eisai media release.
    • 10 Jul 2013 Results of this pivotal paediatric trial were published in Epilepsia, according to an Eisai media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top